| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2023 | 88.76% | Craig-Hallum | $29 → $23 | Maintains | Buy |
| 08/09/2023 | 105.17% | TD Cowen | $29 → $25 | Maintains | Outperform |
| 08/09/2023 | 105.17% | Lake Street | $34 → $25 | Maintains | Buy |
| 07/17/2023 | 138% | Stephens & Co. | $27 → $29 | Maintains | Overweight |
| 07/11/2023 | 138% | Craig-Hallum | → $29 | Initiates Coverage On | → Buy |
| 03/17/2023 | 121.58% | Stephens & Co. | $31 → $27 | Maintains | Overweight |
| 03/06/2023 | 129.79% | Oppenheimer | → $28 | Reiterates | → Outperform |
| 05/10/2022 | 228.27% | Stephens & Co. | $47 → $40 | Maintains | Overweight |
| 05/10/2022 | 146.2% | Keybanc | $60 → $30 | Maintains | Overweight |
| 04/25/2022 | 129.79% | Oppenheimer | → $28 | Upgrades | Perform → Outperform |
| 08/13/2021 | 392.41% | Keybanc | $50 → $60 | Maintains | Overweight |
| 05/14/2021 | — | Benchmark | Downgrades | Buy → Hold | |
| 03/23/2021 | 343.17% | Benchmark | → $54 | Upgrades | Hold → Buy |
| 03/23/2021 | 310.34% | KeyBanc | $40 → $50 | Maintains | Overweight |
| 11/10/2020 | 228.27% | Keybanc | → $40 | Initiates Coverage On | → Overweight |
| 09/22/2020 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 09/18/2020 | 170.82% | Cowen & Co. | → $33 | Initiates Coverage On | → Outperform |
| 08/11/2020 | — | Benchmark | Downgrades | Buy → Hold | |
| 05/04/2020 | 80.55% | B. Riley Securities | $24 → $22 | Maintains | Buy |
| 03/23/2020 | 39.52% | HC Wainwright & Co. | $26 → $17 | Maintains | Buy |
| 03/12/2020 | 96.96% | B. Riley Securities | $27 → $24 | Maintains | Buy |
| 02/24/2020 | 105.17% | Lake Street | → $25 | Initiates Coverage On | → Buy |
| 02/19/2020 | 96.96% | Benchmark | → $24 | Initiates Coverage On | → Buy |
| 02/06/2020 | 121.58% | B. Riley Securities | → $27 | Initiates Coverage On | → Buy |
| 12/16/2019 | 113.38% | HC Wainwright & Co. | $23 → $26 | Reiterates | → Buy |
| 11/21/2019 | 80.55% | Oppenheimer | → $22 | Initiates Coverage On | → Outperform |
| 09/04/2019 | 80.55% | Northland Capital Markets | $18 → $22 | Maintains | Outperform |
| 07/22/2019 | 88.76% | HC Wainwright & Co. | → $23 | Initiates Coverage On | → Buy |
| 10/03/2018 | 80.55% | B. Riley Securities | $23 → $22 | Maintains | Buy |
What is the target price for BioLife Solns (BLFS)?
The latest price target for BioLife Solns (NASDAQ: BLFS) was reported by Craig-Hallum on August 10, 2023. The analyst firm set a price target for $23.00 expecting BLFS to rise to within 12 months (a possible 88.76% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BioLife Solns (BLFS)?
The latest analyst rating for BioLife Solns (NASDAQ: BLFS) was provided by Craig-Hallum, and BioLife Solns maintained their buy rating.
When is the next analyst rating going to be posted or updated for BioLife Solns (BLFS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioLife Solns, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioLife Solns was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
Is the Analyst Rating BioLife Solns (BLFS) correct?
While ratings are subjective and will change, the latest BioLife Solns (BLFS) rating was a maintained with a price target of $29.00 to $23.00. The current price BioLife Solns (BLFS) is trading at is $12.19, which is out of the analyst's predicted range.